Sign In
Last checked at 
21 Jul 2021 07:00
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Nuformix plc
("Nuformix" or the "Company")
Directorate change
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that Dr Anne Brindley has decided to step down as CEO. Anne will continue in her current position for the next six months and has committed to assist the Company with an orderly transition for that period.
Alastair Riddell, Non-Executive Chairman of Nuformix, said: "Anne has been made an exceptional offer by another company which she wants to pursue. She is committed to ensuring the progress of the three assets in the Nuformix portfolio over the next six months and will continue to lead this process. In particular, managing the further preclinical work on NXP002 to deliver a more robust data package, the further research on NXP004 and concluding the licensing discussions on NXP001.
"We will be very sorry to see Anne go but we wish her all the very best in her future pursuits. We look forward to providing further updates to shareholders on the development of the portfolio of assets in the coming months."
Enquiries:
Nuformix plc | via Walbrook | ||||
Dr Alastair Riddell, Non-Executive Chairman |
| ||||
Dr Anne Brindley, CEO |
| ||||
|
| ||||
Allenby Capital Limited | +44 (0) 20 3328 5656 | ||||
Nick Athanas / George Payne (Corporate Finance) |
| ||||
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking) |
| ||||
|
| ||||
Walbrook PR | nuformix@walbrookpr.com or +44 (0)20 7933 8780 | ||||
Anna Dunphy / Paul McManus / Kiki Zaccagnini | Tel: +44 (0)7876 741 001 / +44 (0)7980 541 893 | ||||
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.
Follow the stocks
